Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II low-dose deferasirox in non-transfusion-dependent myelodysplastic syndrome
2017-001258-33Phase 2Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by CHU Grenoble Alpes. Primary endpoint: Percentage of patients without transfusion dependence at 12 months. Started Jul 2017; status: completed.
02
Drugs
deferasirox
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2017-001258-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001258-33.